Indoleamine 2,3-dioxygenase 1 (IDO1)
Indoleamine 2,3-dioxygenase 1 (IDO1) is a protein-coding gene that encodes an enzyme involved in tryptophan catabolism along the kynurenine pathway.
Indoleamine 2,3-dioxygenase 1 (IDO1) is a protein-coding gene that encodes an enzyme involved in tryptophan catabolism along the kynurenine pathway. In biomedical research, IDO1 is widely recognized as an immunoregulatory factor because its activity can contribute to local tryptophan depletion and the accumulation of immunosuppressive metabolites, thereby shaping T-cell responses and broader tumor immune microenvironments. For this reason, IDO1 is often discussed as a non-classical immune checkpoint rather than a conventional receptor-ligand checkpoint.
In cancer and inflammatory disease contexts, IDO1 has been studied as a mechanism of immune escape and treatment resistance. It is frequently considered alongside pathways involving STAT1, dendritic cell activation, STING1 signaling, and CD274 molecule-mediated immune suppression. Recent work has also linked IDO1 to mitochondrion-associated signaling and to the immunosuppressive behavior of cancer-associated fibroblast-rich tumor stroma, underscoring its relevance in breast cancer and other solid tumors.
Where the papers sit
10 papers from the last 6 months study Indoleamine 2,3-dioxygenase 1 (IDO1) directly · updated from PubMed 15 Nov 2026
Study type 1 clinical trial · 1 human data · 8 preclinical
Themes no clear themes · 1 paradigm shift · 1 new direction
Those 10 do not share a common subject.
-
IDO1 inhibition and IDO1–kynurenine signaling recur across cancer, transplantation, diabetes, and rheumatoid arthritis studies. Several papers pursue dual IDO1/TDO or NMT/IDO1 inhibitors, including approaches that also modulate SHP-2 or ABCB1. Other work combines IDO1-targeting with photothermal therapy, nivolumab, radiation, or methotrexate. The applications and mechanisms are too varied to establish a single direction.
IDO1–kynurenine pathway activation can be therapeutic rather than intrinsically immunosuppressive
METTL3-overexpressing insulin-producing cell grafts in streptozotocin-induced diabetic mice and Erzhi pill combined with methotrexate in collagen-induced arthritis rats were both reported to benefit from restoring IDO1–kynurenine signaling. This contrasts with the prevailing assumption in the set that IDO1 activity is chiefly a tumor-associated immunosuppressive mechanism to be inhibited. In the diabetes model, increased IDO1 and kynurenine improved graft survival and reduced endogenous islet apoptosis, while in rheumatoid arthritis, pathway restoration improved osteoblast function, restrained osteoclastogenesis, and reduced bone loss; these findings make IDO1 activation context-dependent and identify pathway enhancement, rather than blockade, as a therapeutic direction in distinct noncancer settings 42406422Jul 42208105May.
IDO1 can drive cancer progression through noncatalytic SHP-2 signaling in addition to kynurenine production
Compound 66, an ortho-benzamidourea dual IDO1/TDO inhibitor tested in tumor cells, was developed on the assumption that IDO1 is principally a catalytic enzyme whose cancer relevance can be addressed by suppressing its enzymatic activity. Instead, the study linked IDO1 to a noncatalytic IDO1–SHP-2 interaction that promoted cancer-cell proliferation and migration, and showed that compound 66 could attenuate this signaling while also reducing kynurenine-pathway output. This expands IDO1 from a metabolic immune checkpoint into a target with separable catalytic and signaling functions, supporting modulation of both rather than catalytic inhibition or complete degradation alone 42483959Jul.
Papers
The 10 papers from the last 6 months that study Indoleamine 2,3-dioxygenase 1 (IDO1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (10)
- Design, synthesis, and biological evaluation of novel dual-functional NMT/IDO-1 inhibitors with fungicidal and immunomodulatory activities. Bioorganic chemistry · 31 Oct 2026 PMID 42966225
- Single in situ intratumoral low‑dose shikonin hydrogel plus mild photothermal therapy elicits systemic antitumor immunity in immune‑cold triple‑negative breast cancer. International journal of oncology · 21 Aug 2026 PMID 42627061
- Discovery of a Dual IDO1/TDO Inhibitor That Modulates Enzymatic Activity and IDO1/SHP-2 Signaling. Journal of medicinal chemistry · 22 Jul 2026 PMID 42483959
- Discovery of a novel miconazole analogue as a dual apo-IDO1 inhibitor and ABCB1 modulator for cancer immunotherapy and chemosensitizing. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 11 Jul 2026 PMID 42435917
- METTL3-Activated IDO1-Kynurenine Pathway in Insulin-Producing Cells Enhances Graft Survival and Attenuates Endogenous Islet Apoptosis in Diabetic Mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 6 Jul 2026 PMID 42406422
- A Comparative Study of Mesenchymal Stem Cell Derived From Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Through a Trophoblast-like Stage and Bone Marrow-derived Mesenchymal Stem Cells in Treating Acute Xenogeneic Graft-versus-host Disease in Humanized Mice. Transplantation · 9 Jun 2026 PMID 42260632
- Integrated Network Pharmacology and Machine Learning to Reveal the Mechanisms of Schisandrin A Against Triple-Negative Breast Cancer. Journal of cellular and molecular medicine · 1 Jun 2026 PMID 42220063
- A Reproducible Hierarchical Virtual Screening Framework Integrating Scaffold-Aware Machine Learning, Ensemble Docking, and Molecular Dynamics: Application to IDO1. Journal of chemical information and modeling · 29 May 2026 PMID 42210816
- Erzhi pill enhances methotrexate efficacy in rheumatoid arthritis bone homeostasis via activation of the IDO1-KYN-AhR pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology · 28 May 2026 PMID 42208105
- Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 May 2026 PMID 42189896
By study type
Clinical trials (1)
- Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 May 2026 PMID 42189896
Human data, design not indexed (1)
- A Reproducible Hierarchical Virtual Screening Framework Integrating Scaffold-Aware Machine Learning, Ensemble Docking, and Molecular Dynamics: Application to IDO1. Journal of chemical information and modeling · 29 May 2026 PMID 42210816
Preclinical: animal, cell and lab studies (8)
- Design, synthesis, and biological evaluation of novel dual-functional NMT/IDO-1 inhibitors with fungicidal and immunomodulatory activities. Bioorganic chemistry · 31 Oct 2026 PMID 42966225
- Single in situ intratumoral low‑dose shikonin hydrogel plus mild photothermal therapy elicits systemic antitumor immunity in immune‑cold triple‑negative breast cancer. International journal of oncology · 21 Aug 2026 PMID 42627061
- Discovery of a Dual IDO1/TDO Inhibitor That Modulates Enzymatic Activity and IDO1/SHP-2 Signaling. Journal of medicinal chemistry · 22 Jul 2026 PMID 42483959
- Discovery of a novel miconazole analogue as a dual apo-IDO1 inhibitor and ABCB1 modulator for cancer immunotherapy and chemosensitizing. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 11 Jul 2026 PMID 42435917
- METTL3-Activated IDO1-Kynurenine Pathway in Insulin-Producing Cells Enhances Graft Survival and Attenuates Endogenous Islet Apoptosis in Diabetic Mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 6 Jul 2026 PMID 42406422
- A Comparative Study of Mesenchymal Stem Cell Derived From Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Through a Trophoblast-like Stage and Bone Marrow-derived Mesenchymal Stem Cells in Treating Acute Xenogeneic Graft-versus-host Disease in Humanized Mice. Transplantation · 9 Jun 2026 PMID 42260632
- Integrated Network Pharmacology and Machine Learning to Reveal the Mechanisms of Schisandrin A Against Triple-Negative Breast Cancer. Journal of cellular and molecular medicine · 1 Jun 2026 PMID 42220063
- Erzhi pill enhances methotrexate efficacy in rheumatoid arthritis bone homeostasis via activation of the IDO1-KYN-AhR pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology · 28 May 2026 PMID 42208105
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.